View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 13, 2022

Zavation Medical secures 510k clearance for lumbar interbody fusion device

The eZspand Lateral needs no secondary locking, which reduces the number of steps necessary for procedures.

Zavation Medical Products has received 510k clearance from the US Food and Drug Administration (FDA) for its expandable lumbar interbody fusion device, eZspand Lateral.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

Part of the Zavation eZspand Interbody System, the eZspand Lateral device offers an optimal fit for individual patients through expandable precision as well as continual expansion.

This provides improved structural stability and sagittal balance.

The company stated that the new lumbar interbody fusion device does not require secondary locking, which reduces the number of steps necessary for procedures.

The eZspand Lateral’s cage has a lordosis of up to 15° and can backfill with bone graft. Each implant can expand up to 6mm from the insertion height, creating a large graft window and enabling fusion.

Zavation Medical noted that the continuous height adjustment, up to 6mm expansion and no secondary locking step distinguishes the eZspand Lateral from its competitors.

Zavation Medical CEO Jeffrey Johnson said: “Our product development team’s dedication to creatively blending simplicity and precision in a robust product design has produced an expandable product that we believe is the new gold standard in facilitating patient fusion in a seamless and simplified procedure.

“With restoration of alignment being of critical importance, the eZspand Lateral was developed to help surgeons address stability and sagittal alignment while maximising lordotic correction.

“This product is an example of Zavation’s commitment to offering innovative and differentiated products in conjunction with market-leading customer service to best serve our surgeons and distributor network.”

The company noted that implants in the Zavation eZspand Interbody System are developed for use with autogenous bone grafts in skeletally mature patients during spinal fusion procedures.

They are intended for use at either one level or two contiguous levels, from L2 to S1, in the lumbar spine to treat degenerative disc disease (DDD) with up to Grade I spondylolisthesis.

Zavation Medical stated that patients who have completed six months of non-operative treatment will be eligible for treatment using the device.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network